Mateon Therapeutics to Present at the Rodman & Renshaw Investor Conference on September 6, 2018

SOUTH SAN FRANCISCO, Calif., Aug. 30, 2018 (GLOBE NEWSWIRE) — Mateon Therapeutics, Inc. (OTCQB:MATN), a biopharmaceutical company developing drugs for the treatment of orphan oncology indications, today announced it will provide an overview of the company and its programs at the 20th Annual Rodman & Renshaw Global Investment Conference.

Mateon’s presentation is scheduled to occur on Thursday, September 6, 2018 at 3:00 p.m. eastern time. To listen to a live webcast of the presentation, please visit the Company’s website, Under the “Investors & News” tab, select the link to “Events & Presentations.” A replay of the webcast will be available at the same location following the conclusion of the live event.

About Mateon
Mateon Therapeutics, Inc. is a biopharmaceutical company developing investigational drugs for the treatment of orphan oncology indications, with programs in acute myeloid leukemia and immuno-oncology. Mateon is committed to leveraging its product development expertise and intellectual property to bring improved and medically necessary new therapies to cancer patients worldwide.


Mateon Therapeutics, Inc.
Matthew M. Loar